RLAY – relay therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Wells Fargo & Company to an "overweight" rating.
Will Relay Therapeutics (RLAY) Board Additions Signal a Shift in Commercialization Strategy? [Yahoo! Finance]
Relay Therapeutics (NASDAQ:RLAY) had its price target raised by analysts at Wells Fargo & Company from $4.00 to $6.00. They now have an "equal weight" rating on the stock.
Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: Commodore Capital LP
Form 4 Relay Therapeutics, Inc. For: Nov 04 Filed by: COATS LONNEL
Form 4 Relay Therapeutics, Inc. For: Nov 04 Filed by: Dable Habib J
Form 3 Relay Therapeutics, Inc. For: Nov 04 Filed by: COATS LONNEL
Form 3 Relay Therapeutics, Inc. For: Nov 04 Filed by: Dable Habib J
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.